BZFD vs. TOI, ANGH, NHTC, PLBY, KUKE, CLOE, WFCF, UONEK, BODI, and IMAQ
Should you be buying BuzzFeed stock or one of its competitors? The main competitors of BuzzFeed include Oncology Institute (TOI), Anghami (ANGH), Natural Health Trends (NHTC), PLBY Group (PLBY), Kuke Music (KUKE), Clover Leaf Capital (CLOE), Where Food Comes From (WFCF), Urban One (UONEK), Beachbody (BODI), and International Media Acquisition (IMAQ).
Oncology Institute (NASDAQ:TOI) and BuzzFeed (NASDAQ:BZFD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.
In the previous week, Oncology Institute had 8 more articles in the media than BuzzFeed. MarketBeat recorded 16 mentions for Oncology Institute and 8 mentions for BuzzFeed. Oncology Institute's average media sentiment score of 0.73 beat BuzzFeed's score of -0.34 indicating that BuzzFeed is being referred to more favorably in the news media.
Oncology Institute has higher revenue and earnings than BuzzFeed. BuzzFeed is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.
Oncology Institute received 2 more outperform votes than BuzzFeed when rated by MarketBeat users. Likewise, 66.67% of users gave Oncology Institute an outperform vote while only 11.11% of users gave BuzzFeed an outperform vote.
36.9% of Oncology Institute shares are held by institutional investors. Comparatively, 37.6% of BuzzFeed shares are held by institutional investors. 9.5% of Oncology Institute shares are held by insiders. Comparatively, 20.3% of BuzzFeed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Oncology Institute has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, BuzzFeed has a beta of 3.1, indicating that its share price is 210% more volatile than the S&P 500.
Oncology Institute currently has a consensus target price of $2.25, indicating a potential upside of 235.82%. Given BuzzFeed's higher possible upside, equities analysts plainly believe Oncology Institute is more favorable than BuzzFeed.
Oncology Institute has a net margin of -24.56% compared to Oncology Institute's net margin of -32.51%. Oncology Institute's return on equity of -52.57% beat BuzzFeed's return on equity.
Summary
Oncology Institute beats BuzzFeed on 10 of the 17 factors compared between the two stocks.
Get BuzzFeed News Delivered to You Automatically
Sign up to receive the latest news and ratings for BZFD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BZFD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BuzzFeed Competitors List
Related Companies and Tools
